Advertisement
Screener

Metagenomi Therapeutics, Inc. (MGX) Graph

MGX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $22.51M; Operating expenses $28.52M; Income tax $0.00.
  • 2026-03-31: Revenue $1.25M; Research and development $19.30M; Operating expenses $25.84M; Income tax $10.00K.
  • 2025-12-31: Revenue $3.91M*; Research and development $21.50M*; Operating expenses $28.28M*; Income tax $34.00K*.
  • 2025-09-30: Revenue $8.66M; Research and development $25.28M; Operating expenses $31.50M; Income tax -$234.00K.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$22.51M$28.52M$0.00-$27.48M
2026-03-31$1.25M$19.30M$25.84M$10.00K-$23.06M
2025-12-31$3.91M*$21.50M*$28.28M*$34.00K*-$22.53M*
2025-09-30$8.66M$25.28M$31.50M-$234.00K-$20.39M
2025-06-30$8.51M$22.51M$29.50M$44.00K-$19.91M
2025-03-31$4.13M$25.14M$31.95M$98.00K-$25.04M
2024-09-30$11.51M$26.26M$33.90M-$2.11M-$18.77M
2024-06-30$20.01M$28.32M$36.87M-$2.20M-$10.74M
2024-03-31$11.16M$31.44M$40.19M$0.00-$25.15M
2023-09-30$12.36M$26.84M$34.76M$1.21M-$19.82M
2023-06-30$11.34M$22.68M$29.30M$1.90M-$13.01M
2023-03-31$8.66M$20.13M$26.59M-$2.20M-$16.13M

Revenue and expense 6 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$41.81M$54.35M$10.00K-$50.54M
2025-06-30$12.64M$47.65M$61.45M$142.00K-$44.95M
2024-06-30$31.17M$59.76M$77.06M-$2.20M-$35.89M
2023-06-30$19.99M$42.81M$55.90M$4.09M-$29.14M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30$21.30M$72.93M$92.94M-$92.00K-$65.34M
2024-09-30$42.68M$86.02M$110.96M-$4.30M-$54.66M
2023-09-30$32.36M$69.65M$90.65M$5.30M-$48.96M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31$25.21M$94.43M$121.22M-$58.00K-$87.87M
2024-12-31$52.30M$109.18M$141.20M-$5.51M-$78.06M
2023-12-31$44.76M$94.40M$123.25M$8.03M-$68.25M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Scilex Holding Co (SCLX)United States$0.042B-0.14
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Instil Bio, Inc. (TIL)United States$0.048B-1.73
Tevogen Inc. (TVGN)United States$0.049B
aTYR PHARMA INC (ATYR)United States$0.033B-0.98
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Quince Therapeutics, Inc. (QNCX)United States$0.031B
CEL SCI CORP (CVM)United States$0.030B-0.81
BioAtla, Inc. (BCAB)United States$0.058B-0.21